TARA · Insider Trading
Protara Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by TARA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-01 | Jesse Shefferman | CEO and President | MIXED | −30,000 | −$470.20K |
| 2026-06-16 | Barry P Flannelly | Director | A | +31,000 deriv. | — |
| 2026-06-16 | Cynthia Smith | Director | A | +31,000 deriv. | — |
| 2026-06-16 | Michael Edward Solomon | Director | A | +31,000 deriv. | — |
| 2026-06-16 | Richard S Levy | Director | A | +31,000 deriv. | — |
| 2026-06-16 | Jane Huang | Director | A | +31,000 deriv. | — |
| 2026-06-16 | Gregory Sargen | Director | A | +31,000 deriv. | — |
| 2026-06-16 | Luke M Beshar | Director | A | +31,000 deriv. | — |
| 2026-06-16 | Roger Garceau | Director | A | +31,000 deriv. | — |
| 2026-06-03 | William Conkling | Chief Commercial Officer | F | −6,008 | −$26.07K |
| 2026-04-09 | Jacqueline Zummo | Chief R&D Officer | Sell | −1,134 | −$6.12K |
| 2026-04-02 | Jacqueline Zummo | Chief R&D Officer | Sell | −22,598 | −$118.87K |
| 2026-01-27 | Patrick Fabbio | Chief Financial Officer | F | −3,261 | −$21.75K |
| 2026-01-27 | Jesse Shefferman | CEO and President | F | −8,732 | −$58.24K |
| 2026-01-27 | Hannah Fry | VP, Controller | F | −1,457 | −$9.72K |
| 2026-01-27 | Jacqueline Zummo | Chf Scientific Operations Off | F | −3,724 | −$24.84K |
| 2026-01-22 | Hannah Fry | VP, Controller | F | −2,132 | −$11.94K |
| 2026-01-22 | Jacqueline Zummo | Chf Scientific Operations Off | F | −6,578 | −$36.84K |
| 2026-01-22 | Patrick Fabbio | Chief Financial Officer | F | −3,063 | −$17.15K |
| 2026-01-22 | Jesse Shefferman | CEO and President | F | −16,322 | −$91.40K |
| 2026-01-21 | Patrick Fabbio | Chief Financial Officer | A | +28,000 | — |
| 2026-01-21 | Leonardo Viana Nicacio | Chief Medical Officer | A | +26,000 | — |
| 2026-01-21 | William Conkling | Chief Commercial Officer | A | +26,000 | — |
| 2026-01-21 | Jacqueline Zummo | Chf Scientific Operations Off | A | +30,000 | — |
| 2026-01-21 | Jesse Shefferman | CEO and President | A | +87,000 | — |
| 2026-01-21 | Hannah Fry | VP, Controller | A | +9,500 | — |
| 2025-07-07 | Jesse Shefferman | CEO and President | G | −300,000 | — |
| 2025-06-30 | Jesse Shefferman | CEO and President | G | −18,667 | — |
| 2025-06-13 | Richard S Levy | Director | A | +24,000 deriv. | — |
| 2025-06-13 | Jane Huang | Director | A | +24,000 deriv. | — |
| 2025-06-13 | Michael Edward Solomon | Director | A | +24,000 deriv. | — |
| 2025-06-13 | Luke M Beshar | Director | A | +24,000 deriv. | — |
| 2025-06-13 | Gregory Sargen | Director | A | +24,000 deriv. | — |
| 2025-06-13 | Cynthia Smith | Director | A | +24,000 deriv. | — |
| 2025-06-13 | Barry P Flannelly | Director | A | +24,000 deriv. | — |
| 2025-06-13 | Roger Garceau | Director | A | +24,000 deriv. | — |
| 2025-06-04 | William Conkling | Chief Commercial Officer | A | +50,000 | — |
| 2025-05-19 | Richard S Levy | Director | Buy | +20,000 | +$63.80K |
| 2025-05-16 | Richard S Levy | Director | Buy | +20,000 | +$63.80K |
| 2025-04-17 | Leonardo Viana Nicacio | Chief Medical Officer | A | +50,000 | — |
| 2025-03-28 | Jacqueline Zummo | Chf Scientific Operations Off | Sell | −21,224 | −$96.14K |
| 2025-03-28 | Hannah Fry | VP, Controller | — | — | — |
| 2025-03-28 | Jacqueline Zummo | Chf Scientific Operations Off | — | — | — |
| 2025-03-28 | Jesse Shefferman | CEO and President | — | — | — |
| 2025-03-28 | Patrick Fabbio | Chief Financial Officer | — | — | — |
| 2025-01-28 | Patrick Fabbio | Chief Financial Officer | A | +23,500 | — |
| 2025-01-28 | Hannah Fry | VP, Controller | A | +9,500 | — |
| 2025-01-28 | Jesse Shefferman | CEO and President | A | +65,000 | — |
| 2025-01-28 | Jacqueline Zummo | Chf Scientific Operations Off | A | +24,500 | — |
| 2025-01-23 | Hannah Fry | VP, Controller | F | −2,130 | −$10.14K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jesse Shefferman | CEO and President | 991,832 | $2.67M |
| Luke M Beshar | Director | 198,000 | $532.62K |
| Jacqueline Zummo | Chief R&D Officer | 94,827 | $255.08K |
| Leonardo Viana Nicacio | Chief Medical Officer | 78,181 | $210.31K |
| William Conkling | Chief Commercial Officer | 69,992 | $188.28K |
| Patrick Fabbio | Chief Financial Officer | 64,115 | $172.47K |
| Richard S Levy | Director | 51,000 | $137.19K |
| Hannah Fry | VP, Controller | 42,723 | $114.92K |
| Roger Garceau | Director | 33,000 | $88.77K |
| Gregory Sargen | Director | 31,000 | $83.39K |
| Michael Edward Solomon | Director | 26,500 | $71.28K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TARA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.